



BioMarker
STRATEGIES

News Release

Contact:

Scott Allocco, President

410-522-1008

FOR IMMEDIATE RELEASE

Tuesday, April 20

BioMarker Strategies Awarded \$75,000 through TEDCO's Maryland Technology Transfer Fund for SnapPath™ System

Baltimore, Md—April 20, 2009—BioMarker Strategies, a cancer-diagnostics company based at the Johns Hopkins Science + Technology Park in Baltimore, has received \$75,000 in funding from TEDCO's Maryland Technology Transfer Fund (MTTF) and the Johnson & Johnson Corporate Office of Science & Technology (COSAT), to expedite the development of the novel SnapPath™ live-tumor-cell testing system. The SnapPath™ system is being developed by BioMarker Strategies to test live tumor cells after biopsy to determine the most effective cancer-drug treatment. These predictive, ex-vivo biomarker tests are not possible using current tumor-tissue processing methods.

Karen Olson, CEO of BioMarker Strategies, stated: "We thank TEDCO and Johnson & Johnson COSAT for their financial support which will help us expedite the development of the SnapPath™ live-tumor-cell testing system. We also appreciate Governor O'Malley's commitment to biotechnology and thank the Maryland General Assembly for reauthorizing the biotechnology tax credit program that spurs investment in biomedical innovation in our state."

"TEDCO is extremely proud of the award-winning MTTF program and the support we have been able to provide emerging companies in Maryland," said Renée Winsky, president and executive director of TEDCO. "We are excited to be able to support innovative companies like BioMarker Strategies which are focused on enabling molecular diagnostics and personalized medicine for cancer."

BioMarker Strategies, which has a sponsored-research agreement with Johns Hopkins, is developing a novel automated tumor biopsy processing and testing system, called SnapPath™, that is being designed to quickly test and analyze a patient's live tumor sample at the point of care. The company is also developing a series of unique, pathway-based, ex vivo biomarker tests to help guide an oncologist's use of targeted cancer therapeutics. The SnapPath™ technology is also being designed to reduce patient waiting times for molecular diagnostic test results from several weeks to several hours. The company (www.biomarkerstrategies.com) is one of the first commercial tenants at the Johns Hopkins Science + Technology Park in East Baltimore developed and managed by the Forest City-New East Baltimore Partnership. The company's CEO, Karen Olson, was recently awarded the "Leadership in BioScience Award" by the Greater Baltimore Committee.

News Release

The Maryland Technology Development Corporation (TEDCO), an independent entity, was established by the Maryland General Assembly in 1998 to facilitate the creation of businesses and foster their growth in all regions of the State. TEDCO's role is to be Maryland's leading source of funding for seed capital and entrepreneurial business assistance for the development, transfer and commercialization of technology. TEDCO connects emerging technology companies with federal laboratories, research universities, business incubators and specialized technical assistance. For the fifth consecutive year, TEDCO was recognized as the most active seed/early-stage investor in the nation in the August 2008 issue of Entrepreneur magazine and received the national Excellence in Technology-Based Economic Development award from the State Science and Technology Institute (SSTI) for the Maryland Technology Transfer Fund (MTTF) program in October 2008. For more information on TEDCO and its programs and resources, visit www.MarylandTEDCO.org.

###